Actualités et vidéos - ORION CLASS B - Anglais

ORION CORPORATION STOCK EXCHANGE RELEASE – CHANGES BOARD/MANAGEMENT/AUDITORS 19 DECEMBER 2024 at 22.45 EET CORRECTION: Change in Orion Group Executive Management Board as of 1 June 2025 – Mikko Kemppainen appointed General Counsel Orion corrects the stock exchange release published on 19 December at 19.00 EET. In the original English stock exchange release the first quote by CEO Liisa Hurme differs from the first quote in the Finnish stock exchange release. The quote in the Finnish version...

ORION CORPORATION STOCK EXCHANGE RELEASE – CHANGES BOARD/MANAGEMENT/AUDITORS 19 DECEMBER 2024 at 19.00 EET Change in Orion Group Executive Management Board as of 1 June 2025 – Mikko Kemppainen appointed General Counsel Olli Huotari , Senior Vice President responsible for Corporate Functions organization of the Orion Group and Secretary to the Board of Directors of Orion Corporation, and a member of the Executive Management Board of the Orion Group informed earlier of his decision to leave...

ORION CORPORATION PRESS RELEASE 18 DECEMBER 2024 at 17.00 EET Orion and Abilita Therapeutics announce research collaboration and option to license agreement to develop innovative antibody therapeutics Orion Corporation (“Orion”) and Abilita Therapeutics (“Abilita”) announced today that they have entered into a research collaboration and option to license agreement to develop innovative antibody therapeutics in the areas of oncology and pain. Under the terms of the agreement, Orion gains...

ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 12 DECEMBER 2024 at 20.30 EET Penalty payment to a member of Orion’s Board of Directors for delay in notifying managers’ transaction In accordance with the applicable regulations, Orion Corporation discloses the following information: The Financial Supervisory Authority (FIN-FSA) has imposed a penalty payment of EUR 6,000 on Ari Lehtoranta, a member of the Board of Directors of...

ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 27 NOVEMBER 2024 at 9.00 EET 142,701 Orion Corporation A shares converted into B shares In accordance with Section 3 of the Articles of Association of Orion Corporation, 142,701 A shares have been converted into 142,701 B shares. The conversion has been entered into the Trade Register on 27 November 2024. The total number of shares in Orion Corporation is 141,134,278 which, after the...

Orion Research Foundation grants EUR 1,109,000 for research in 2025 Press release 22 November, 2024 at 9.00 EET Orion Research Foundation sr is distributing EUR 1,109,000 in research grants based on applications for 2025. Orion Research Foundation awards grants of max EUR 50,000 for 19 researchers for postdoctoral research and max EUR 6,000 for 93 young researchers for doctoral dissertation work. Orion Research Foundation sr is annually distributing its return on investment and donations from...

ORION CORPORATION INVESTOR NEWS 19 NOVEMBER 2024 at 18.30 EET Orion and Alligator Bioscience amend their agreement concerning two bispecific antibodies Orion Corporation and Alligator Bioscience AB have agreed on the conversion of the previously granted royalty-bearing license to Orion Corporation to two bispecific antibodies that the companies have been successfully developing in collaboration using Alligator’s RUBY® bispecific format to a perpetual, fully paid, royalty-free license. Orion...

ORION CORPORATION MANAGERS’ TRANSACTIONS 1 NOVEMBER 2024 at 9.45 EET Orion Corporation: Managers’ transactions – Henrik Stenqvist Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons. Orion Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement...

ORION CORPORATION INTERIM REPORT 1–9/2024 29 OCTOBER 2024 at 12:00 EET Orion Group Interim Report January–September 2024 Net sales totalled EUR 1,108.0 (January–September 2023: 868.5) million Operating profit was EUR 323.8 (182.0) million Basic earnings per share were EUR 1.83 (1.01) Cash flow from operating activities per share was EUR 1.46 (0.50) The outlook for 2024 was upgraded during the reporting period on 11 September 2024: Net sales are estimated to be EUR 1,470 million to EUR...

ORION CORPORATION STOCK EXCHANGE RELEASE – INSIDE INFORMATION 24 OCTOBER 2024 at 19.50 EEST Inside information: Orion terminates ODM-111 development program due to narrow therapeutic window of the molecule Orion Corporation has decided to terminate the ODM-111 development program based on the risk-benefit analysis on the results of a longer non-clinical toxicology study. Recent findings indicate that the profile of the ODM-111 molecule does not support long-term use of ODM-111 and progression...

ORION CORPORATION PRESS RELEASE 15 OCTOBER 2024 at 9.00 EEST Orion publishes Interim Report for January–September 2024 and holds a webcast on 29 October 2024 Orion will publish Interim Report for January–September 2024 on Tuesday, 29 October 2024 at approximately 12.00 noon EET. The release and related presentation material will be available on the company’s website at www.orion.fi/en/investors after publishing. Webcast and conference call A webcast and a conference call for analysts,...

ORION CORPORATION INVESTOR NEWS 14 OCTOBER 2024 at 11.00 EEST Orion’s collaboration partner Bayer submits application for third indication of darolutamide in the EU Orion’s collaboration partner Bayer today announced the submission of an application to the European Medicines Agency (EMA) for the oral androgen receptor inhibitor (ARi) darolutamide. Bayer is seeking approval for the use of darolutamide in combination with androgen deprivation therapy (ADT) in patients with metastatic...

ORION CORPORATION PRESS RELEASE 30 SEPTEMBER 2024 at 10.00 a.m. EEST Orion’s near-term climate targets approved by the Science Based Targets initiative Orion Corporation is proud to announce that the Science Based Targets initiative (SBTi) has validated our near-term science-based targets. This means that our greenhouse gas (GHG) emissions reduction targets align with the latest climate science to limit global warming to 1.5°C above pre-industrial levels. Orion Corporation commits to reduce...

ORION CORPORATION INVESTOR NEWS 26 SEPTEMBER 2024 at 11.00 EEST Orion’s collaboration partner Bayer submits application to U.S. FDA for third indication of darolutamide which has become the first ever Orion-originated blockbuster Orion’s collaboration partner Bayer today announced the submission of a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) for the oral androgen receptor inhibitor (ARi) darolutamide. Bayer is seeking approval for the use of...

ORION CORPORATION PRESS RELEASE 25 SEPTEMBER 2024 at 15.00 EEST Orion and Aitia enter AI-Driven Drug Discovery and Drug Simulation Collaboration in Oncology Orion Corporation and Aitia, an AI-enabled biotechnology company and the leader in the development and application of Causal AI and "Digital Twins" to discover and develop new drugs, announced today that the companies have entered into agreement to create new Gemini Digital Twins to help in the fight against cancer. Cancer is a critical...

ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 20 SEPTEMBER 2024 at 9.30 EEST 213,285 Orion Corporation A shares converted into B shares In accordance with Section 3 of the Articles of Association of Orion Corporation, 213,285 A shares have been converted into 213,285 B shares. The conversion has been entered into the Trade Register on 20 September 2024. The total number of shares in Orion Corporation is 141,134,278 which, after...

ORION CORPORATION PRESS RELEASE 16 SEPTEMBER 2024 at 11.30 EEST Darolutamide plus androgen deprivation therapy significantly reduced the risk of radiological progression or death by 46% compared to placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer Results from the pivotal Phase III ARANOTE trial evaluating darolutamide plus androgen deprivation therapy (ADT) showed a statistically significant increase in radiological progression-free survival (rPFS) compared to...

ORION CORPORATION STOCK EXCHANGE RELEASE – INSIDE INFORMATION 11 SEPTEMBER 2024 at 09:30 EEST Inside information: Orion upgrades full-year outlook for 2024 Orion Corporation upgrades the full-year outlook for 2024 both for the part regarding net sales and operating profit. Orion’s product sales and royalty income has continued to grow faster than expected during the second half of 2024 and this good development is anticipated to continue during the remainder of the year. Due to these...

ORION CORPORATION MANAGERS’ TRANSACTIONS 22 AUGUST 2024 at 10.30 EEST Orion Corporation: Managers’ transactions – Satu Ahomäki Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons. Orion Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement...

ORION CORPORATION MANAGERS’ TRANSACTIONS 21 AUGUST 2024 at 18.45 EEST Orion Corporation: Managers’ transactions – Niclas Lindstedt Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons. Orion Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement...